| 32.8 1.14 (3.6%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.39 | 1-year : | 46.01 |
| Resists | First : | 33.72 | Second : | 39.39 |
| Pivot price | 30.29 |
|||
| Supports | First : | 25.51 |
Second : | 20.44 |
| MAs | MA(5) : | 32.36 |
MA(20) : | 29.35 |
| MA(100) : | 19.3 |
MA(250) : | 18.7 |
|
| MACD | MACD : | 2.8  |
Signal : | 2.8 |
| %K %D | K(14,3) : | 80.3 |
D(3) : | 85.3 |
| RSI | RSI(14): 71.2 |
|||
| 52-week | High : | 33.72 | Low : | 9.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below upper band by 15.0%. Bollinger Bands are 41.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 32.9 - 33.03 | 33.03 - 33.14 |
| Low: | 31.1 - 31.26 | 31.26 - 31.4 |
| Close: | 32.52 - 32.78 | 32.78 - 33.01 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Sat, 27 Sep 2025
Arrowhead Pharmaceuticals Inc. (ARWR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Wed, 24 Sep 2025
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week High - What's Next? - MarketBeat
Mon, 22 Sep 2025
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year High - Still a Buy? - MarketBeat
Fri, 19 Sep 2025
Rhumbline Advisers Has $4.41 Million Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Thu, 11 Sep 2025
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Business Wire
Wed, 10 Sep 2025
H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 77.4 (%) |
| Shares Short | 12,730 (K) |
| Shares Short P.Month | 12,940 (K) |
| EPS | -1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.77 |
| Profit Margin | -25.9 % |
| Operating Margin | -596.3 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -37.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 4.14 |
| Sales Per Share | 4.14 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -27.34 |
| PEG Ratio | 0 |
| Price to Book value | 8.67 |
| Price to Sales | 7.91 |
| Price to Cash Flow | 207.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|